FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043297692> ?p ?o ?g. }

• W2043297692 endingPage "4688" @default.
• W2043297692 startingPage "4688" @default.
• W2043297692 abstract "Abstract E7449 is an orally bioavailable, potent, small molecule inhibitor of Poly(ADP-ribose) Polymerase (PARP)1 and PARP2. PARP1 is a key molecule in sensing and repairing single strand DNA breaks via the base excision repair (BER) pathway and may also play a role in the repair of double strand DNA breaks. Both PARP1 and PARP2 are activated upon DNA damage with PARP1 activity accounting for the majority of the PARP response. Inhibition of PARP impairs DNA repair and potentiates the efficacy of DNA damaging chemotherapy and radiotherapy for cancer treatment. Additionally, PARP inhibition is effective as a single agent cancer therapy where there is an underlying defect in double strand DNA repair by homologous recombination (e.g., BRCA mutation). In this study we describe the development of the novel PARP inhibitor E7449. E7449 potently inhibits PARP1 and PARP2 in a cell-free assay and potentiates the cytotoxicity of both radiotherapy and chemotherapy. The cytotoxic effect of radiotherapy was enhanced by E7449 in clonogenic survival assays. The anti-tumor activity of the alkylating agent temozolomide was potentiated by E7449 in a dose responsive manner in vivo in the B16-F10 melanoma isograft mouse model. Daily dosing of E7449 as a single agent significantly inhibited tumor growth in a genetically engineered BRCA1 null mouse ovarian xenograft model. In the BRCA1 mutant human breast cancer cell line MDA-MB-436, E7449 significantly inhibited proliferation in a long term growth inhibition assay in vitro. Oral administration of E7449 once daily potently inhibited tumor growth in the MDA-MB-436 xenograft model with no toxicity observed. A dose responsive pharmacodynamic effect on PARP activity was demonstrated in MDA-MB-436 tumor tissue following administration of a single E7449 dose. The decrease in PARP activity was sustained over several hours. The ability of E7449 to inhibit PARP activity in tumor tissue was further investigated in the H460 xenograft model. Following single oral administration of various E7449 dosages, inhibition of PARP activity in tumor tissue was determined over time. Studies revealed that PARP is inhibited by E7449 in a time and dose dependent manner with lower doses resulting in transient inhibition and higher doses causing more complete and sustained PARP inhibition. Conclusion: E7449 is a potent and selective PARP1 and PARP2 inhibitor with potent anti-tumor activity in BRCA-deficient in vivo models. It also potentiates the activity of radiotherapy and chemotherapy pre-clinically. Evaluation of E7449 in a Phase 1 study will be initiated soon. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4688. doi:1538-7445.AM2012-4688" @default.
• W2043297692 created "2016-06-24" @default.
• W2043297692 creator A5031053642 @default.
• W2043297692 creator A5033009316 @default.
• W2043297692 creator A5043461259 @default.
• W2043297692 creator A5047113286 @default.
• W2043297692 creator A5066927624 @default.
• W2043297692 creator A5069813415 @default.
• W2043297692 creator A5090570108 @default.
• W2043297692 date "2012-04-01" @default.
• W2043297692 modified "2023-10-14" @default.
• W2043297692 title "Abstract 4688: E7449: A novel PARP inhibitor enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors" @default.
• W2043297692 doi "https://doi.org/10.1158/1538-7445.am2012-4688" @default.
• W2043297692 hasPublicationYear "2012" @default.
• W2043297692 type Work @default.
• W2043297692 sameAs 2043297692 @default.
• W2043297692 citedByCount "2" @default.
• W2043297692 countsByYear W20432976922013 @default.
• W2043297692 countsByYear W20432976922020 @default.
• W2043297692 countsByYear W20432976922023 @default.
• W2043297692 crossrefType "journal-article" @default.
• W2043297692 hasAuthorship W2043297692A5031053642 @default.
• W2043297692 hasAuthorship W2043297692A5033009316 @default.
• W2043297692 hasAuthorship W2043297692A5043461259 @default.
• W2043297692 hasAuthorship W2043297692A5047113286 @default.
• W2043297692 hasAuthorship W2043297692A5066927624 @default.
• W2043297692 hasAuthorship W2043297692A5069813415 @default.
• W2043297692 hasAuthorship W2043297692A5090570108 @default.
• W2043297692 hasConcept C117262875 @default.
• W2043297692 hasConcept C121608353 @default.
• W2043297692 hasConcept C134935766 @default.
• W2043297692 hasConcept C143425029 @default.
• W2043297692 hasConcept C153911025 @default.
• W2043297692 hasConcept C182979987 @default.
• W2043297692 hasConcept C187206112 @default.
• W2043297692 hasConcept C207001950 @default.
• W2043297692 hasConcept C2777389519 @default.
• W2043297692 hasConcept C2778227246 @default.
• W2043297692 hasConcept C2778480876 @default.
• W2043297692 hasConcept C2779138821 @default.
• W2043297692 hasConcept C2779962180 @default.
• W2043297692 hasConcept C2781312401 @default.
• W2043297692 hasConcept C502942594 @default.
• W2043297692 hasConcept C54355233 @default.
• W2043297692 hasConcept C552990157 @default.
• W2043297692 hasConcept C55493867 @default.
• W2043297692 hasConcept C82381507 @default.
• W2043297692 hasConcept C86803240 @default.
• W2043297692 hasConcept C96232424 @default.
• W2043297692 hasConcept C98274493 @default.
• W2043297692 hasConceptScore W2043297692C117262875 @default.
• W2043297692 hasConceptScore W2043297692C121608353 @default.
• W2043297692 hasConceptScore W2043297692C134935766 @default.
• W2043297692 hasConceptScore W2043297692C143425029 @default.
• W2043297692 hasConceptScore W2043297692C153911025 @default.
• W2043297692 hasConceptScore W2043297692C182979987 @default.
• W2043297692 hasConceptScore W2043297692C187206112 @default.
• W2043297692 hasConceptScore W2043297692C207001950 @default.
• W2043297692 hasConceptScore W2043297692C2777389519 @default.
• W2043297692 hasConceptScore W2043297692C2778227246 @default.
• W2043297692 hasConceptScore W2043297692C2778480876 @default.
• W2043297692 hasConceptScore W2043297692C2779138821 @default.
• W2043297692 hasConceptScore W2043297692C2779962180 @default.
• W2043297692 hasConceptScore W2043297692C2781312401 @default.
• W2043297692 hasConceptScore W2043297692C502942594 @default.
• W2043297692 hasConceptScore W2043297692C54355233 @default.
• W2043297692 hasConceptScore W2043297692C552990157 @default.
• W2043297692 hasConceptScore W2043297692C55493867 @default.
• W2043297692 hasConceptScore W2043297692C82381507 @default.
• W2043297692 hasConceptScore W2043297692C86803240 @default.
• W2043297692 hasConceptScore W2043297692C96232424 @default.
• W2043297692 hasConceptScore W2043297692C98274493 @default.
• W2043297692 hasIssue "8_Supplement" @default.
• W2043297692 hasLocation W20432976921 @default.
• W2043297692 hasOpenAccess W2043297692 @default.
• W2043297692 hasPrimaryLocation W20432976921 @default.
• W2043297692 hasRelatedWork W2003243316 @default.
• W2043297692 hasRelatedWork W2016425953 @default.
• W2043297692 hasRelatedWork W2283134145 @default.
• W2043297692 hasRelatedWork W2807317098 @default.
• W2043297692 hasRelatedWork W2901011044 @default.
• W2043297692 hasRelatedWork W2914979195 @default.
• W2043297692 hasRelatedWork W3009707110 @default.
• W2043297692 hasRelatedWork W3134914296 @default.
• W2043297692 hasRelatedWork W3135348276 @default.
• W2043297692 hasRelatedWork W4296617455 @default.
• W2043297692 hasVolume "72" @default.
• W2043297692 isParatext "false" @default.
• W2043297692 isRetracted "false" @default.
• W2043297692 magId "2043297692" @default.
• W2043297692 workType "article" @default.